Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Rockefeller University The Rogosin Institute Memorial Sloan-Kettering Cancer Center |
---|---|
Information provided by: | Rockefeller University |
ClinicalTrials.gov Identifier: | NCT00792155 |
Autosomal dominant polycystic kidney disease (PKD) is the most common inherited kidney disease, affecting more than 400,000 people in the U.S. and 5 million people worldwide. PKD is the 4th most common cause of kidney failure requiring dialysis and/or transplantation. Over half of all PKD patients develop kidney failure by age 60 years, although age of onset of kidney disease varies widely, even among members of the same family.
Despite the fact this is a relatively common problem, relatively few patients have been studied for a sufficient period of time to fully understand how patients are affected over the course of their lifetime. The reason for creating this repository is to collect information about PKD so that the investigators may fully understand its complications, including high blood pressure, heart attack, and stroke. This information may also aid in the development of improved treatment strategies.
Condition |
---|
Polycystic Kidney Disease |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | Autosomal Dominant Polycystic Kidney Disease Data Repository |
Visit #1:
- An initial detailed history, physical examination, and laboratory evaluation
The following imaging procedures will be performed within three months of the first study visit:
Follow-up Study Visits:
- Patients will return to the outpatient facility for detailed follow-up examinations every other year after Visit 1.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
All patients enrolled in this study will have the diagnosis of autosomal dominant kidney disease. Diagnostic criterion is the presence of a total of 5 cysts in both kidneys, or, for patients older than 65 years, more than 4 cysts in each kidney. Genotyping is not routinely performed in clinical practice; therefore, this information will not be available as a diagnostic criterion for most patients prior to enrollment.
Inclusion Criteria:
Exclusion Criteria:
Contact: Stephanie Donahue, NP | 212-746-1591 | donahus@rockefeller.edu |
Contact: Ines Chicos, CCRC | 212-746-3541 |
United States, New York | |
The Rockefeller University Hospital | Recruiting |
New York, New York, United States, 10065 | |
Contact: Caryne Roey 212-327-8409 croey@rockefeller.edu | |
The Rogosin Institute | Recruiting |
New York, New York, United States, 10021 | |
Contact: Stephanie Donahue, NP 212-746-1591 donahus@rockefeller.edu |
Principal Investigator: | Jon Blumenfeld, MD | The Rogosin Institute |
Principal Investigator: | Stephanie Donahue, NP | The Rogosin Institute |
Responsible Party: | The Rogosin Institute ( Jon Blumenfeld, MD ) |
Study ID Numbers: | JBL-0496 |
Study First Received: | November 14, 2008 |
Last Updated: | November 14, 2008 |
ClinicalTrials.gov Identifier: | NCT00792155 |
Health Authority: | United States: Institutional Review Board |
PKD |
Urologic Diseases Polycystic Kidney, Autosomal Dominant Kidney Diseases, Cystic Polycystic Kidney Diseases Kidney Diseases |